Age-Based Treatment Plan Study for MDS Stem Cell Transplant
Part of Blood & lymphatic clinical trials.
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with low- or intermediate-risk MDS (myelodysplastic syndromes).
- You are receiving a stem cell transplant from a half-matched family donor (haploidentical).
- You do not have a matched sibling or unrelated donor available.
- You do not have high-risk MDS.
- You do not have an active infection, organ failure, or other serious health issues.
- You are willing and able to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.